000			01940nam a2200457 i 4500
999			_c282437 _d282437
001			on1101623152
003			OCoLC
005			20190708142128.0
006			m o d f
007			cr bn||||a||||
008			190517m20199999dcu o f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1008-I (online)
086	0		_aY 1.1/8:116-55/
099			_aY 1.1/8:116-55/
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce,
245	1	0	_aCreating and Restoring Equal Access to Equivalent Samples Act of 2019 : _breport (to accompany H.R. 965) (including cost estimate of the Congressional Budget Office).
264		1	_a[Washington, D.C.] : _b[U.S. Government Publishing Office], _c[2019]-
300			_a1 online resource (volumes).
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
490	1		_aRept. / 116th Congress, 1st session, House of Representatives ; _v116-55
500			_a"Supplemental report"--Pt. 3.
500			_a"May 10, 2019"--Pt. 1-2.
500			_a"May 16, 2019"--Pt. 3.
500			_aCRDP Program record.
588			_aDescription based on online resource, PDF version; title from Pt. 1 caption (govinfo, viewed May 17, 2019).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. _tCreating and Restoring Equal Access to Equivalent Samples Act of 2019 _w(OCoLC)1101623370
810	1		_aUnited States. _bCongress. _bHouse. _tReport ; _v116-55.
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo120587
050		4	_aKF32 _b.E55 2019c
650		0	_aGeneric drugs _xPrices _zUnited States.
650		0	_aPharmaceutical industry _zUnited States.
650		0	_aCompetition _zUnited States.
650		0	_aDrugs _xPrices _zUnited States.
655		7	_aLegislative materials. _2lcgft
942			_2sudocs _c8